<DOC>
	<DOCNO>NCT02701257</DOCNO>
	<brief_summary>This study compare two different model wearable bionic pancreas device ( iPhone-based bionic pancreas vs. iLet bionic pancreas ) adult participant type 1 diabetes . Both bionic pancreas device measure glucose level every five minute give insulin and/or glucagon automatically regulate blood glucose ( BG ) . The iPhone bionic pancreas use early study , volunteer use system 11 day time live normal life home work . The iLet bionic pancreas never test human . In new study , volunteer participate train visit learn device work . They use iPhone-based BP 1 day iLet BP 1 day random order use Lilly glucagon . They use iLet BP one additional day use Xeris Xerisol glucagon ( stable formulation human glucagon ) .</brief_summary>
	<brief_title>The iLet Introduction Study : A Feasibility Study iLet , Fully Integrated Bihormonal Bionic Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Age ≥ 18 year clinical type 1 diabetes least one year Diabetes manage use insulin pump ≥ 6 month Prescription medication regimen stable &gt; 1 month ( except medication affect safety study expect affect outcome study , judgment principal investigator ) Unable provide inform consent ( e.g . impaired cognition judgment ) Unable safely comply study procedure report requirement ( e.g . impairment vision dexterity prevents safe operation bionic pancreas , impaired memory , unable speak read English ) Current participation another diabetesrelated clinical trial , judgment principal investigator , compromise result study safety subject Pregnancy ( positive urine HCG ) , breast feeding , plan become pregnant immediate future , sexually active without use contraception Current alcohol abuse ( intake average &gt; 3 drink daily last 30 day ) , use marijuana within 1 month enrollment , substance abuse ( use within last 6 month control substance marijuana without prescription ) Unwilling unable refrain study day : acetaminophen form use marijuana use drug may dull sensorium , reduce sensitivity symptom hypoglycemia , hind decision make period participation study ( use beta blocker allow long dose stable subject meet criterion hypoglycemia unawareness take stable dose , use benzodiazepine narcotic , even prescription , may exclude accord judgment principal investigator ) History liver disease expect interfere antihypoglycemia action glucagon ( e.g . liver failure cirrhosis ) . Other liver disease ( i.e . active hepatitis , steatosis , active biliary disease , tumor liver , hemochromatosis , glycogen storage disease ) may exclude subject cause significant compromise liver function may unpredictable fashion . Renal failure dialysis Personal history cystic fibrosis , pancreatitis , pancreatic tumor , pancreatic disease besides type 1 diabetes Any known history coronary artery disease include , limited , history myocardial infarction , stress test showing ischemia , history angina , history intervention coronary artery bypass grafting , percutaneous coronary intervention , enzymatic lysis presume coronary occlusion ) Congestive heart failure ( establish history CHF , low extremity edema , paroxysmal nocturnal dyspnea , orthopnea ) History TIA stroke Seizure disorder , history nonhypoglycemic seizure within last two year , ongoing treatment anticonvulsant History hypoglycemic seizure ( grandmal ) coma last year History pheochromocytoma : fractionate metanephrines test patient history increase risk catecholamine secrete tumor : Episodic treatment refractory ( require 4 medication achieve normotension ) hypertension Paroxysms tachycardia , pallor , headache Personal family history MEN 2A , MEN 2B , neurofibromatosis , von HippelLindau disease History adrenal disease tumor Hypertension systolic BP ≥160 mm Hg diastolic BP ≥100 despite treatment Untreated inadequately treat mental illness ( indicator would include symptoms psychosis , hallucination , mania , psychiatric hospitalization last year ) , treatment antipsychotic medication know affect glucose regulation . Electrically powered implant ( e.g . cochlear implant , neurostimulators ) might susceptible RF interference History adverse reaction glucagon ( include allergy ) besides nausea vomit Established history allergy severe reaction adhesive tape must use study Use oral ( e.g . thiazolidinediones , biguanides , sulfonylurea , glitinides , DPP4 inhibitor , SGLT2 inhibitor ) antidiabetic medication Any factor , opinion principal investigator would interfere safe completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Bionic Pancreas</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Continuous Glucose Monitor</keyword>
</DOC>